Capital Fund Management (CFM)
MLTX icon

Capital Fund Management (CFM)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Buy
+11,260
New +$187K ﹤0.01% 2000
2024
Q3 		– Sell
-29,243
Closed -$1.29M – 2086
2024
Q2 		$1.29M Buy
+29,243
New +$1.24M ﹤0.01% 1536

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Fund Management (CFM)'s MLTX Position: Q1 2026 in Review

Capital Fund Management (CFM) opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 11,260 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #2000 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in MLTX as recently as Q2 2024.

Capital Fund Management (CFM) first reported a position in MLTX in Q2 2024 and has held it in 2 quarters since. The position peaked at $1.29M in Q2 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Capital Fund Management (CFM) held 11,260 shares of MoonLake Immunotherapeutics worth $210K as of Q1 2026.
  • MoonLake Immunotherapeutics was a new Capital Fund Management (CFM) position in Q1 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #2000 holding.
  • Capital Fund Management (CFM) first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 2 quarters since.
  • Capital Fund Management (CFM)'s MoonLake Immunotherapeutics position peaked at $1.29M in Q2 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.